Pantogar's Sales cut in half
By | translator Choi HeeYoung
21.03.04 12:07:48
가나다라
0
Import ceased from the middle of last year due to changes in overseas manufacturing sites
It will be re-imported within the year
Achieved ₩1.3 billion in 2019, decreased 53.8% to ₩600 million last year
According to the pharmaceutical industry on the 4th, import of Pantogar has been temporarily suspended from the middle of last year due to changes in overseas manufacturing sites.
It was sold out as Pantogar's domestic distribution was stopped. Pantogar is out of stock at major online pharmaceutical shopping malls.
This caused Pantogar's sales to plummet. According to the pharmaceutical market research firm IQVIA, Pantogar sales decreased 53.8% from about ₩1.3 billion in 2019 to ₩600 million last year.
Pantogar's competitors include DongKook's Pansidil a
(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)